Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

CLASS ACTION UPDATE for CTST, GTT and ABMD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

CNTTQ

NEW YORK, NY / ACCESSWIRE / August 9, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.

CannTrust Holdings Inc. (NYSE:CTST)

Lawsuit on behalf of: investors who purchased November 14, 2018 - July 12, 2019
Lead Plaintiff Deadline : September 9, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/canntrust-holdings-inc-loss-form?prid=2860&wire=1

According to filed complaints, CannTrust Holdings Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was growing cannabis in its Pelham greenhouse while applications for regulatory approval were still pending; (2) the Company’s Pelham greenhouse did not comply with certain regulations; (3) as a result, the Company was reasonably likely to face an inventory hold by Health Canada until the Pelham facility becomes compliant with applicable regulations; (4) as a result, the Company’s customers would face shortages and would likely seek product from CannTrust’s competitors; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

GTT Communications, Inc. (NYSE:GTT)

Lawsuit on behalf of: investors who purchased February 26, 2018 - July 1, 2019
Lead Plaintiff Deadline : September 30, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/gtt-communications-inc-loss-form?prid=2860&wire=1

According to the filed complaint, during the class period, GTT Communications, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) following GTT's acquisition of Interoute Communications Holdings S.A., there were delays in migrating Interoute’s legacy systems and processes into GTT’s client management database system; (2) Interoute had made a strategic priority shift to sell cloud services that was a higher percentage of Interoute’s sales in the two years leading up to the acquisition; (3) a material percentage of the Interoute sales representatives were not productive at selling GTT’s core cloud networking services; (4) GTT was unable to yield as many Interoute salespeople because Interoute had hired many sales people focused on cloud services and allowed underperforming sales representatives to remain at Interoute; and (5) as a result of the foregoing, Defendants’ public statements were materially false and/or misleading and/or lacked a reasonable basis.

Abiomed, Inc. (NASDAQGS: ABMD)

Lawsuit on behalf of: investors who purchased January 31, 2019 - July 31, 2019
Lead Plaintiff Deadline : October 7, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/abiomed-inc-loss-form?prid=2860&wire=1

According to the filed complaint, during the class period, Abiomed, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Abiomed’s revenue growth was in decline; (ii) the Company did not have a sufficient plan in place to stem its declining revenue growth; (iii) the Company was unlikely to restore its revenue growth over the next several fiscal quarters; (iv) consequently, Abiomed was reasonably likely to revise its full-year 2020 guidance in a way that would fall short of the Company’s prior projections and market expectations; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/555394/CLASS-ACTION-UPDATE-for-CTST-GTT-and-ABMD-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today